Ethereum whales scoop up ETH worth $74M – Any effect on the price?

ambcryptoPublished on 2026-01-23Last updated on 2026-01-23

Abstract

Ethereum's price has declined, hovering around $2,944, down 2.2% daily and 11% weekly. Despite the bearish pressure, whales have been actively accumulating ETH. One whale purchased 20,013 ETH worth $59 million, while another bought 5,099 ETH worth $15.14 million after three months of inactivity. In total, whales acquired 25,112 ETH valued at $74.14 million, indicating strong demand in the $2.9k to $3.1k range. However, this whale activity has not offset the overall market selling pressure. Bearish momentum persists, and if it continues, ETH could drop to $2.5k before a potential rise to $3.4k in early February.

Since Ethereum’s price breached its $3k support level, it has hovered around $2.9k. At the time of writing, the altcoin was valued at $2,944, down 2.2% on the daily charts and 11% on the weekly charts.

Its sustained decline is indicative of intense bearish pressure. However, with ETH showing upside weakness, investors, especially whales, have grabbed the chance to accumulate ETH lately.

Whale continue to ‘buy the dip’

With ETH hovering below $3,000, whales have been on an accumulation spree. According to Onchain Lens, a whale bought 20,013 ETH worth approximately $59 million from FalconX.

Just a week ago, this whale bought 10,000 ETH for $28.9 million and sent $58 million to Wintermute for future purchases. After the latest purchase, the whale now holds 80,115 $ETH worth $236.55M.

Additionally, another whale purchased 5,099 ETH worth $15.14 million from Kraken after being dormant for 3 months. In total, the two whales scooped up 25,112 ETH worth $74.14 million.

Here, it’s worth pointing out that these two whales are not isolated cases either. Looking at the Spot Average Order Size, a hike in whale participation has been evident throughout January so far.

The metric showed large whale orders dominated between the price ranges of $2.9k and $3.1k – Signaling aggressive whale demand.

Often, a hike in whale participation could mean either buying or selling. In this case, the altcoin’s Spot Taker CVD has remained positive throughout this period. A positive CVD implies that buy orders are dominant. Hence, in this particular case, whales have been active on the demand side of the market.

Often, an increase in whale buying activity during a downturn is also indicative of confidence in the market. Especially if they believe another leg up might be inevitable.

Can whales lift ETH’s price?

While whales have aggressively accumulated ETH, their buying pressure has failed to offset market pressure so far.

In fact, a look at the DMI Stochastic Momentum Index (DMI-SMI) revealed that the bearish momentum has accelerated, not stabilized.

To put it simply, markets have settled into a bearish regime, and retail traders have sold at every bounce, making the whales’ attempts insignificant so far.

Such a momentum configuration is a sign of bearish trend continuation or sideways chop, before the market attempts another leg up. Therefore, if whales continue to accumulate while reducing downside pressure, Ethereum will remain stuck between $2.8k and $3.1k.

However, if the bearish momentum accelerates further and overwhelms whale demand, ETH is likely to breach its lower boundary.

Based on the altcoin’s Future Grand Trend, ETH could breach $2.8k and drop to $2.5k, before rising to $3.4k in early February.


Final Thoughts

  • Ethereum whales have been buying the dip, scooping up 25,112 ETH worth $74.14 million.
  • Ethereum [ETH] continues to face intense bearish pressure, making whale activity inadequate for another leg up.

Trending Cryptos

Related Questions

QWhat is the current price of Ethereum and how has it performed recently?

AAt the time of writing, Ethereum (ETH) was valued at $2,944, down 2.2% on the daily charts and 11% on the weekly charts.

QHow much ETH did the two whales mentioned in the article accumulate and what was its total value?

AThe two whales scooped up a total of 25,112 ETH, which was worth approximately $74.14 million.

QAccording to the article, what does a positive Spot Taker CVD indicate about whale activity?

AA positive Spot Taker CVD implies that buy orders are dominant, indicating that whales have been active on the demand side of the market.

QDespite the whale accumulation, why has the price of ETH continued to face downward pressure?

AThe bearish momentum has accelerated, and retail traders have been selling at every bounce, making the whales' buying pressure inadequate to offset the overall market selling pressure so far.

QWhat are the two potential price scenarios for Ethereum outlined in the article's forecast?

AOne scenario is that ETH remains stuck between $2.8k and $3.1k if whales continue to accumulate. The other is that if bearish momentum accelerates, ETH could breach $2.8k and drop to $2.5k before potentially rising to $3.4k in early February.

Related Reads

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

On August 18th, Haowei Huaxin, a semiconductor firm specializing in gallium arsenide and gallium nitride wafers, reported that over a hundred individuals forcibly entered its offices and seized the company's official seals from a safe, including the corporate, contract, and party committee seals. The incident is the latest escalation in a protracted control dispute. Haowei Huaxin, established in 2010, was originally a joint venture. Control became contested after 2021 when Zhenwei Financial Holding injected capital, becoming the largest shareholder (34.01%), while former parent Haite High-Tech's stake was diluted to 33.79%. An agreed-upon governance structure collapsed, leading to mutual accusations. Haite claimed it was locked out of the subsidiary's premises, while also alleging improper management like livestock being kept on the chip fabrication site. After state-owned Qingdao Haiyue Holdings took over Zhenwei's stake in 2023, Haite accused it of illegally seizing control. Despite Haite winning several legal battles in 2024-2026, which affirmed its rights to nominate directors and the chairman, it failed to regain physical control or recover the seals. The stakes are high: market valuations for Haite's stake in Haowei Huaxin are estimated between 3.7 to 5 billion USD, yet it is only valued at about 83 million USD on Haite's books. Losing control effectively jeopardizes a significant portion of Haite's value. In response to the seal seizure, Haite framed it as a "shareholder rights protection" action agreed upon by five shareholders. This mirrors a pattern in Chinese corporate disputes where seizing physical seals becomes a tactic to paralyze the opponent's daily operations, seen in past conflicts at companies like Dangdang and Bitmain. However, such actions don't resolve underlying ownership issues; the opposing party can report the seals stolen, declare them void, and apply for new ones, albeit with significant delay. The incident underscores how fragile corporate governance can devolve into physical confrontations over symbols of authority, with control ultimately determined by law and shareholding, not possession of a seal.

marsbit35m ago

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

marsbit35m ago

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

Bernstein's analysis of Moderna's 177% stock surge following positive Phase 3 results for its individualized neoantigen therapy (INT) in melanoma distinguishes fundamental drivers from market speculation. The clinical breakthrough is real: the INTerpath-001 trial met its primary and key secondary endpoints, providing crucial validation for mRNA technology in oncology beyond infectious diseases. However, Bernstein argues the magnitude of the stock move cannot be justified by this single trial's fundamentals alone. The surge was amplified by three key factors: 1) A re-rating of Moderna's mRNA platform potential for expansion into other cancers, 2) A massive short squeeze, given ~15% of shares were sold short pre-announcement, and 3) The compelling "cancer vaccine" narrative that fueled broader investor enthusiasm. While the melanoma success is significant, Bernstein cautions that replication in lung, kidney, and bladder cancers—which have different immunogenicity—is not guaranteed. Furthermore, INT's commercial model faces challenges: it's a personalized treatment, not a mass-market vaccine, implying higher production costs and potential margin pressures despite a projected multi-billion dollar peak sales opportunity. The report also notes sector rotation, with some funds moving from crowded AI/semiconductor trades into defensive healthcare stocks, adding further momentum. In conclusion, Bernstein maintains a "Market-Perform" rating and a $45 price target, far below the post-surge price. It views the current valuation as pricing in an optimistic multi-cancer platform success and efficient commercialization that are yet to be proven. The clinical inflection point is clear, but the earnings inflection point awaits validation across future trials and commercial execution.

marsbit35m ago

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

marsbit35m ago

Trading

Spot

Hot Articles

Discussions

Welcome to the HTX Community. Here, you can stay informed about the latest platform developments and gain access to professional market insights. Users' opinions on the price of ETH (ETH) are presented below.

活动图片